{"filing":{"accession_number":"0001935979-26-000067","cik":"0001935979","ticker":"BHVN","company_name":"Biohaven Ltd.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"bhvn-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000067/bhvn-20260810.htm"},"events":[{"id":26634,"run_id":24212,"accession_number":"0001935979-26-000067","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Biohaven's financial results for Q2 2026 (ended June 30, 2026), including R\u0026D expenses ($100.8M), G\u0026A expenses ($24.1M), net loss ($137.3M or $0.91 per share), and cash position ($270.5M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes both financial metrics and operational highlights (clinical trial progress, pipeline updates) typical of a quarterly earnings announcement.","company_name":"Biohaven Ltd.","ticker":"BHVN","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27828,"accession_number":"0001935979-26-000067","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Biohaven's financial results for Q2 2026 (ended June 30, 2026), including R\u0026D expenses ($100.8M), G\u0026A expenses ($24.1M), net loss ($137.3M or $0.91 per share), and cash position ($270.5M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes both financial metrics and operational highlights (clinical trial progress, pipeline updates) typical of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:31:59.133429+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27828,"accession_number":"0001935979-26-000067","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Biohaven's financial results for Q2 2026 (ended June 30, 2026), including R\u0026D expenses ($100.8M), G\u0026A expenses ($24.1M), net loss ($137.3M or $0.91 per share), and cash position ($270.5M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes both financial metrics and operational highlights (clinical trial progress, pipeline updates) typical of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:31:59.133429+00:00","company_name":"Biohaven Ltd.","ticker":"BHVN","filing_date":"2026-08-10"}]}